Coronavirus: reports on immunizations

26 March 2020

  • Euroclear (CT, USA) procures permit to build up an expansive range hostile to viral specialist that could treat Coronavirus, with starting research center outcomes showing a significant level of movement against Coronavirus
  • Sorrento (CA, USA) dispatches novel STI-6991 I-Cell Coronavirus cell antibody program
  • Vencor and Virk Biotechnology (both CA, USA) enter permit understanding for utilization of Xtend XmAb immunizer innovation for exploring antibodies as expected medicines for patients with Coronavirus
  • Murdoch Kids’ Exploration Foundation (Australia) to trial BCG immunization against Coronavirus
  • Alleviation Therapeutics (Switzerland) and Nearer Inc (DE, USA) document an Investigational New Medication application with the US FDA for a stage II preliminary of RLF-100 (Aviptadil) in the treatment of Coronavirus incited Intense and Moderate Respiratory Misery

25 March 2020

  • Specialists at Duke-NUS Clinical School (Singapore) plan to begin testing a Coronavirus antibody up-and-comer not long from now
  • Mateon (CA, USA) reports positive outcomes for different Coronavirus drug up-and-comers
  • Vir Biotechnology (CA, USA) to continue with two clinical advancement contender for Coronavirus after announcing that it has recognized various human monoclonal immunizer improvement applicants that kill SARS-CoV-2
  • Clinical investigation from Ascletis Pharma (China) utilizing danoprevir with ritonavir to treat guileless and experienced Coronavirus patients has yielded promising outcomes

24 March 2020

FDA approves Phase III trial of Actemra, developed by Roche (Swizerland), for hospitalised patients with severe COVID-19 pneumonia

23 March 2020

  • Bayer (Germany), Novartis (Switzerland) and Teva (Israel) donate chloroquine and hydroxychloroquine in hopes antimalarials are effective against COVID-19
  • UK clinical testing on an Oxford University (UK) COVID-19 vaccine candidate dubbed ChAdOx1 could begin as early as next month

20 March 2020

  • Roche (Basel, Switzerland) announce they have initiated a Phase III study to investigate the use of Actemra/RoActemra (tocilizumab) plus standard-of-care in hospitalised adults with severe COVID-19 pneumonia compared to placebo plus standard of care
  • Study results published in the New England Journal Of Medicine suggest that the addition of AbbVie’s (IL, USA) Kaletra (lopinavir/ritonavir) to standard care in seriously ill patients with confirmed COVID-19 did not significantly shorten the time to clinical improvement and also not significantly lower mortality rates, compared to standard care alone

18 March 2020

In trials conducted on 200 patients in Wuhan and Shenzhen, Fujifilm’s (Tokyo, Japan) Avigan was shown to reduce pneumonia symptoms, while subjects who received the drug tested negative for the SARS-CoV-2 virus in a shorter time

17 March 2020

  • Moderna (MA, USA) has announced that the first participants have been dosed in a Phase I study of their mRNA candidate vaccine against SARS-CoV-2, the virus that causes COVID-19
  • Pfizer (Zurich, Switzerland) and BioNTech (Germany) on Tuesday said they have agreed to co-develop an mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection, building on a previous R&D collaboration focused on influenza
  • Regeneron Pharmaceuticals (NY, USA) state that it hopes to enter clinical studies with a multi-antibody cocktail that can be administered as prophylaxis for COVID-19 by early summer

16 March 2020

  • Sanofi (Paris, France) and Regeneron Pharmaceuticals (NY, USA)  announce that they have initiated a clinical programme evaluating whether IL-6 inhibition with Kevzara (sarilumab) is better than current supportive care alone for patients hospitalized with severe COVID-19. A Phase II/III study wll be carried out in the USA, led by Regeneron, and will begin enrolling patients immediately
  • BioNTech (Germany) and Fosun Pharmaceutical (China) announce a strategic collaboration to advance BioNTech’s mRNA vaccine candidate BNT162 in China for the prevention of COVID-19 infections
  • CureVac (Tübingen, Germany) said that it “rejects allegations about offers for acquisition of the company or its technology” following reports that US President Donald Trump has sought exclusive access to the German drugmaker’s work on an mRNA-based vaccine against COVID-19

10 March 2020

The Bill & Melinda Gates Foundation (WA, USA) state that it has launched a $125-million seed fund, along with partners Wellcome (London, UK) and Mastercard (NY, USA), to help find potential treatments for COVID-19.

6 March 2020

  • Analysts at RBC Capital Marketing give Gilead’s (CA, USA) remdesivir 50% chance of success as COVID-19 treatment
  • The Coalition for Epidemic Preparedness Innovations (CEPI) put out a call on Friday for $2 billion in new funding to support the development of a vaccine for COVID-19

Check Also

Treatment of 5 Basically Sick Patients With Coronavirus With Recuperating Plasma

Central issues Question Could organization of recuperating plasma bonding be useful in the treatment of …

Leave a Reply

Your email address will not be published. Required fields are marked *